Tag: AYUSH

  • Ayush needs a cure push and not the prevention perception

     

     

    With apologies to none at all

    By Vikas Mehta

     

    Vikas MehtaWith the pandemic many things changed on the health front. Suddenly health and hygiene became a very important part of our lives. In India, with a parallel narrative on health and hygiene existing in the form of ancient methods like yoga, ayurveda, unani (all abbreviated as Ayush), and homeopathy (not strictly Indian but practised widespread), health and hygiene took a very interesting turn.

     

    Whereas the goodness of turmeric and ginger was already part of our modern lifestyle, yoga and ayurveda caught on in a big way. While established companies like Dabur and Baidyanath played it safe by highlighting the benefits of raising body immunity with products like Chyawanprash, Patanjali went headlong and actually claimed to have produced a cure to Corona with Coronil but then beat a hasty retreat to claim that it also is an immunity booster. In fact, currently if you look at the product benefit of Coronil, as listed on Amazon, it says, energy management and for specific uses of product it says, immunity booster

     

    Thisa was also the time that we saw lot of talk on various media including social media on overall wellness and health. Raising body immunity became a catch phrase and anyone related to health started hyping body immunity and how to achieve the same. Green tea, ginger tea, antioxidants, turmeric milk, tulsi drink, immunity bar, were some of the products which became part of the typical middle class family eating habits.

     

    And this was not all, ayurveda doctors and clinics came into big demand. Clinics and private practice mushroomed. Under the guidance of the Ayush ministry, the pandemic saw a growth in ayurveda as a medicinal opportunity. And then there is also a chain of nine ayurveda hospitals and clinics called AyurVAID which has now been acquired by India’s largest chain of hospitals, Apollo Hospitals. Why should an allopathy chain acquire an ayurveda chain of clinics and hospitals? Though that is an intriguing topic, given that allopathy doctors have protested when Ayush doctors were given more powers, including performing minor surgeries, that’s for another day.

     

    The elephant in the room is the viability and the success of traditional concepts like Ayurveda in the post-pandemic era. I don’t have any data on sales of Chyawanprash and many such immunity boosters but I guess their sales must have come down in the past six months or so. To understand why it is difficult to sell concepts like immunity boosters or wellness let’s take the analogy of oral care.

     

    Oral care is largely preventive. Brands like Colgate have to sell a story of prevention, not cure. You do not want cavities and the pain associated with it, start using a toothpaste. You want strong teeth that do not fall away or break, use a toothpaste. Toothpastes are not about cure. They are about prevention. Prevent cavities, prevent teeth from weakening. Prevent gum sensitivity. It’s not that you have toothache and by applying it the ache will go away. It’s the constant use that will prevent any oral problem. And still there is no guarantee that you will not develop cavities or other problems. That’s why in many parts of the world toothpaste penetration is still low. People want cure, not prevention.

     

    That is exactly the issue with alternate treatments. These are not necessary cure. AyurVAID hospitals in the first line describing themselves say “Today’s chronic illnesses require a comprehensive customized and affordable approach to prevention and treatment.” Prevention takes precedence over treatment.

     

    And that is the consumer perception too. The 2015 National Sample Survey says that 90% of Indians prefer allopathy to Ayush. I suspect the reason is simple. Allopathy is about cure. You got pain take x medicine. You have hernia get an operation done. Ayush, on the other hand is about wholistic. Root of the problem. Cure may exist but it will take some time to work. Simply put, the perception is that Allopathy is cure to a problem, Ayush is just prevention. The common man has been attuned to cure. Prevention is not part of the mental make up.

     

    So, when the Pandemic struck and allopathy had no cure, Ayush and its immunity boosters, its turmeric, ginger and tulsi ingredients etc were a great story. People flocked to them as there was no cure. And then came the vaccines. The vaccines were also prevention but armed with research and data, plus government push. In our simplistic minds, a cure to Covid had been found. We no longer needed Ayush. At best, it remained a top up.

     

    For Ayush to succeed it must move into the realm of cure. And to do that it needs to copy a page from the allopathy play book. Get into research and trials in a big way. Publicise the same. And no short-cuts. No sham research. It’s one thing for Baba Ramdev to hit out at allopathy but then by making exaggerated claims without any research backing on ayurveda he is doing a great disservice not just to the practice but also to those who are painstakingly trying to establish that Ayush can be a cure. Flexing his political connections to overturn decisions against Patanjali and its products is actually a sure shot way to create bigger dissonance in the consumer minds.

     

    Ayush also makes tall and sweeping claims. Any pack of Chyawanprash talks about power, mental and physical fitness, agility, increasing resistance and metabolic activity, prevention of infections like cough and cold, effective antioxidant, improving immunity and resistance. The glut of claims make it sound ridiculous and also unbelievable. Chyawanprash may do all that but it needs to focus on its core benefit. And then use science and data to make it come alive. Jack of all trades and master of none can make Ayush a dull and uninterested concept. Not to talk about being non trustworthy.

     

    Almost a decade ago, I had checked into an ayurveda ashram in Kerala for a specific health issue. The founder, an FRCS Doctor and Surgeon, bemoaned the lack of research rigour on ayurveda. He had over decades painstakingly studied Ayurveda and was using his allopathic skills to diagnose the issue and treat it with Ayurveda. He was well aware that Ayurveda was associated with general well being and prevention. He was afraid that ayurveda may just remain a lifestyle generic treatment and may become the preserve of the rich or the foreigners for whom the exoticism of ayurveda is a draw.

     

    Will the taking over of AyurVAID by Apollo Hospitals be the gateway to allopathy playbook that Ayush needs or will it be just another offering of exoticism for the rich and the famous?

     

  • Former ASCI secy gen Shweta Purandare launches ‘Tap-a-Gain’ consultancy

    By Our Staff

     

    Shweta Purandare
    Shweta Purandare

    Former Advertising Standards Council of India (ASCI) secretary general Shweta Purandare has launched ‘Tap-a-Gain’, a boutique consultancy service based in Mumbai. Tap-a-Gain will engage with advertisers, agencies, and small business owners to help them get their advertising communication “First time right” and compliant with advertising regulations.

     

    As was reported by MxMIndia last month, Purandare quit Diageo India where she was heading Corporate Brand and Communications.

     

    As Secretary General of ASCI, Purandare led its transformation over a period of eight years wherein MOUs were established with key regulators such as Department of Consumer Affairs, FSSAI, Ministry of AYUSH and interactions with the Ministry of Information and Broadcasting.

     

    Over her 28+ years career, has experience in product evaluation, product endorsements, advertising claim support, regulatory compliance, Government affairs, Social Media strategy, Grievance redressal and consumer advisory services. She has experience across  multiple sectors such as FMCG, Beautycare, Personal Hygiene, Home care, OTC/ Healthcare, Food and Beverages. She was also the Scientific Director at L’Oreal India heading their product evaluation Centre and Consumer Complaint department. She was a Regulatory Affairs expert at Procter & Gamble India.

     

  • Hamdard launches integrated campaign #StrongWithHamdard

    By A Correspondent

     

    Hamdard Laboratories (Medicine Division has launched a new integrated marketing campaign #StrongWithHamdard emphasising boosting the immune system to stay healthy amid the Covid-19 outbreak.

     

    Commenting on the campaign launch, Suman Varma, Chief Marketing Officer, Hamdard Laboratories (Medicine Division) said: “One of the key measures to stay safe amid the Covid-19 outbreak has been a strong immune system that safeguards us from various infections and the same has been emphasised by the Government and Ministry of AYUSH. As India enters the unlock phase, it becomes even more vital to have a strong immunity that will prevent us against the viral infection,” adding: “Our new campaign #StrongWithHamdard focuses on adopting an alternate medicine system to boost immunity and promote the uses of Unani medicine products to have a strong immunity system.”

     

     

  • ASCI to now control misleading ads of AYUSH drugs

    By A Correspondent

     

    The Ministry of Ayurveda, Yoga and Naturopathy, Unani, Siddha and Homoeopathy (AYUSH) has constituted a committee to control misleading advertisements and exaggerated claims of AYUSH drugs. The Advertising Standards Council of India (ASCI) is the only non-government member in the empowered committee of seven members comprising AYUSH, Health and Family Welfare and DoCA representatives.

     

    The constituted committee will be empowered to review and monitor the implementation of the provisions of The Drugs and Magic Remedies (Objectionable Advertisement) Act, 1954 and Rules there under for curbing misleading advertisements of ASU & H drugs. The committee will be authorised to make recommendations for regulatory action against misleading advertisements and advise the Central Government for issuing any specific directions or advisories and for taking necessary steps. The committee will also be responsible for reviewing the actions taken by the states and the pharmaceutical vigilance centres for surveillance and control of misleading advertisements of ASU & H drugs.

     

    Abanti Sankaranarayanan

    Said ASCI Chairman Abanti Sankaranarayanan: “ASCI has been closely working with AYUSH to ensure that Indian consumers are not exposed to false information and have access to safe drugs. We are confident that the new committee will act as a catalyst to the process of self-regulation in advertising, thus safeguarding consumers from deceptive advertisements that can negatively impact them”.

     

    The meeting of the constituted committee will be convened on a six monthly basis or as and when required to review progress and make recommendations to accomplish their objective of controlling misleading advertisements.

     

     

  • Ayush ministry partners ASCI to co-regulate misleading ads

     

     

    Progressing with the impetus towards supporting co-regulation in advertising, the Ministry of Ayurveda, Yoga and Naturopathy, Unani, Siddha and Homoeopathy (AYUSH) has signed anMoU partnering with the Advertising Standards Council of India (ASCI). Addressing the cases of misleading advertisements with respect to Ayurveda, Yoga and Naturopathy, Unani, Siddha and Homoeopathy Medicines, treatment and related services, ASCI will comprehensively monitor these advertisements across print and electronic media. ASCI has been given a self-monitoring mandate by the Ministry of AYUSH to identify potentially misleading advertisement in the AYUSH sector and process complaints through its Consumer Complaints Council (CCC). The Ministry of AYUSH will also redirect complaints against misleading advertisements they receive to ASCI, which will be reviewed using ASCI’s code and guidelines. The MoU also requires ASCI to report to the Ministry of AYUSH, advertisements in potential violation of the Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954 and Rules thereunder as well as non-compliance of ASCI’s CCC recommendations for the Ministry of AYUSH to take further action.

     

    This partnership will put in place, a much-needed formal mechanism to monitor and curtail misleading advertisements in the AYUSH sector and will lead to effective implementation though strong support locally from the State Licencing Authorities as well as Centrally through the Ministry of AYUSH.

     

    Commenting on the partnership, Ajit M. Sharan, Secretary,  Ministry of AYUSH said: “We are happy to announce this partnership with the ASCI. It is yet another important step taken by the AYUSH ministry to ensure that Indian consumers have access to safe and effective medicine. The arrangement would also ensure that any advertisement making claims for diseases and disorders, in violation of the notification issued by our ministry for indications that have been prohibited from claiming, are immediately brought to our attention. We have entered into anMoU with ASCI to effectively weed out such advertisements so that consumers are protected from unscrupulous manufacturers selling products making false claims. This is vital for the propagation of AYUSH system of medicine within India and beyond.”

     

    Added Srinivasan K Swamy, Chairman, ASCI: “At ASCI, we have been relentlessly working to encourage self-regulation in advertising content and ensuring the protection of the interests of the consumers. AYUSH is among top three sectors where we find a high incidence of misleading advertisements and some of the advertisements in the AYUSH sector claiming treatment of certain diseases in violation of the Drugs and Magic Remedies Regulations have been a cause of concern. ASCI’s partnership with the Ministry of AYUSH will provide the necessary support to our efforts in effectively curtailing misleading advertisements in this sector.”